Multiple Myeloma Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Multiple Myeloma Information Center has current, evidence-based information for you. Get the facts about multiple myeloma early detection, treatment, and survivorship, and stay up to date with ongoing multiple myeloma research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Multiple Myeloma Community is the leading Social Media Application for Multiple Myeloma patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
Daratumumab is a novel anti-CD38 monoclonal antibody that had previously demonstrated single-agent activity in the treatment of multiple myeloma. Imbruvica® Demonstrates Clinical Activity in Relapsed or Refractory Multiple Myeloma
Researchers evaluated potential Imbruvica® dosing regimens either as a single agent or in combination with dexamethasone in the treatment of 69 individuals with relapsed or refractory multiple myeloma. SAR 650948 Anti-CD38 Monoclonal Antibody Appears Promising For the Treatment of Multiple Myeloma
Anti-CD38 monoclonal antibodies could be the next major advance in the treatment of multiple myeloma.
Sarah Holstein, MD, PhD from Roswell Park Cancer Institute recently answered your... Understanding Osteonecrosis of the Jaw
Cancer and its treatment can come with a variety of complications, some more serious... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse...
Multiple Myeloma Management
Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the... Moving Bodies, Changing Lives
Moving On Aerobics helps women regain joy of movement and physical fitness after... Where Kids Can Be Kids… And Cancer Takes a Back Seat
Cancer camps for kids provide fun and camaraderie for children facing down a cancer...
Multiple Myeloma Clinical Trials
06-108 – Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma (MM) Who Are Not Considered Candidates for High-Dose Chemotherapy (HDT) and Autologous Stem Cell Transplantation (SCT): VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan, and Prednisone (VMP) (C05009)
C05009 – Randomized, Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myelome Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE? (Bortezomib) for Injection, Thalidomide, and Dexamethasone (VTD) versus VELCADE? (Bortezomib) and Dexamethasone (VD) versus VELCADE? (Bortezomib), Melphalan and Prednisone (VMP)
MM03 – PHASE II TRIAL OF ARSENIC TRIOXIDE AND THALIDOMIDE IN THE TREATMENT OF PATIENTS WITH REFRACTORY MULTIPLE MYELOMA